Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Enhanced CD34+ cell mobilizations, collections, and comparable safety profile with fixed-dose versus weight-based plerixafor dosing in patients with sickle cell disease receiving autologous CD34+ base-edited hematopoietic stem cells (BEAM-101) in the ongoing BEACON study

View Full Paper
Ask AI
Bookmark
Share

Authors

HFHaydar FrangoulALArthur LoSASrikanth Ambati

Discussion

Loading...

Member takes

Overview

Analysis shows enhanced CD34+ mobilization in sickle cell disease patients with fixed-dose plerixafor, indicating lower adverse events in BEACON study.

Key Points

  • Increased CD34+ cell mobilization was achieved with fixed-dose plerixafor compared to weight-based approach in patients with sickle cell disease.
  • Patients receiving fixed-dose plerixafor had a median of 4 days of apheresis, compared to 6 days with weight-based dosing during mobilization cycles.
  • Analysis utilized leukapheresis to optimize CD34+ cell collection in sickle cell disease patients receiving plerixafor treatment.
  • Lower incidence of adverse events was noted in fixed-dose plerixafor group, suggesting a safer option for mobilization.

Cite This Study

Frangoul et al. (2025) studied this question.

synapsesocial.com/papers/69362f3a4fa91c937236d473https://doi.org/10.1182/blood-2025-1049
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Robust HbF induction and improvement of anemia and hemolysis with base editing in sickle cell disease: Safety and efficacy findings from the ongoing BEACON study2025 · 2 citations
  2. 2An open-label, multi-center Phase 2 study to assess the safety and efficacy of burixafor (GPC-100) and propranolol with G-CSF for the mobilization of hematopoietic progenitor cells in patients with multiple myeloma2025 · 1 citations
  3. 3Etoposide + cytarabine + pegfilgrastim vs cyclophosphamide + granulocyte colony-stimulating factor for stem-cell mobilization in patients with multiple myeloma: A phase III trial2025
  4. 4Efficacy of motixafortide plus G-CSF versus plerixafor plus G-CSF for stem cell mobilization and collection in multiple myeloma: A single-center comparative analysis and interim Results from a prospective study in poor mobilizers2025
  5. 5Eltrombopag plus G-CSF for peripheral blood stem cell mobilization: Final analysis of a single arm, Phase 2 trial2025